RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mochida Pharmaceutical Co Stock

Mochida Pharmaceutical Co Equity 2024

Mochida Pharmaceutical Co Equity

127.97 B JPY

Ticker

4534.T

ISIN

JP3922800002

WKN

859288

In 2024, Mochida Pharmaceutical Co's equity was 127.97 B JPY, a -0.53% increase from the 128.65 B JPY equity in the previous year.

Mochida Pharmaceutical Co Aktienanalyse

What does Mochida Pharmaceutical Co do?

Mochida Pharmaceutical Co Ltd is a Japanese pharmaceutical company based in Tokyo. The company has been in the industry for over 100 years and has become one of the leading providers of medications and health products in Japan and worldwide. The history of Mochida Pharmaceutical begins in 1913 when Shoyo Mochida founded the company. Initially, the company specialized in the production of vitamins and later expanded its product range to include other pharmaceutical products. Over the following decades, the company steadily grew and expanded internationally. Today, Mochida Pharmaceutical is involved in various areas of healthcare. The company offers a wide range of medications for the treatment of various diseases and ailments, including cardiovascular diseases, diabetes, cancer, infectious diseases, and mental illnesses. Mochida Pharmaceutical is also involved in other areas of healthcare. The company manufactures and distributes various medical devices and diagnostics, including a wide range of medical instruments such as endoscopes and ultrasound devices, as well as tests and reagents for the diagnosis of infectious diseases and other conditions. A major focus of Mochida Pharmaceutical's business model is research and development of new products. The company has an extensive research and development department that continuously works on the development of new medications and technologies. Mochida Pharmaceutical collaborates closely with various universities and research institutes to develop new insights and technologies. In addition to the production and distribution of medications and medical devices, Mochida Pharmaceutical is also engaged in health promotion and prevention. The company offers various health services and products aimed at helping people live healthier lives and take better care of their health. Over the years, the company has achieved several important milestones. In 1970, Mochida Pharmaceutical successfully developed an immunosuppressive medication that is now known as Tacrolimus and is used to prevent organ transplant rejection. Other significant milestones include the introduction of medications for the treatment of diabetes and cancer, as well as the development of new technologies such as transdermal patches for medication administration. Mochida Pharmaceutical is now a globally operating company with branches in various countries. The company employs thousands of employees worldwide and has a strong presence in all major markets. The company is committed to further expanding its position as a leading provider of medical products and services and focusing on the needs of its customers and patients. Mochida Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Mochida Pharmaceutical Co's Equity

Mochida Pharmaceutical Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Mochida Pharmaceutical Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Mochida Pharmaceutical Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Mochida Pharmaceutical Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Mochida Pharmaceutical Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Mochida Pharmaceutical Co stock

What is the equity of Mochida Pharmaceutical Co this year?

Mochida Pharmaceutical Co has equity of 127.97 B JPY this year.

What was the equity of Mochida Pharmaceutical Co compared to the previous year?

The equity of Mochida Pharmaceutical Co has increased/decreased by -0.53% decreased compared to the previous year.

What impact does a high equity have on investors of Mochida Pharmaceutical Co?

A high equity is advantageous for investors of Mochida Pharmaceutical Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Mochida Pharmaceutical Co?

A low equity can be a risk for investors of Mochida Pharmaceutical Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Mochida Pharmaceutical Co affect the company?

An increase in equity of Mochida Pharmaceutical Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Mochida Pharmaceutical Co affect the company?

A reduction in equity of Mochida Pharmaceutical Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Mochida Pharmaceutical Co?

Some factors that can affect the equity of Mochida Pharmaceutical Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Mochida Pharmaceutical Co so important for investors?

The equity of Mochida Pharmaceutical Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Mochida Pharmaceutical Co take to change the equity?

To change equity, Mochida Pharmaceutical Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Mochida Pharmaceutical Co pay?

Over the past 12 months, Mochida Pharmaceutical Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 2.31 %. For the coming 12 months, Mochida Pharmaceutical Co is expected to pay a dividend of 83.96 JPY.

What is the dividend yield of Mochida Pharmaceutical Co?

The current dividend yield of Mochida Pharmaceutical Co is 2.31 %.

When does Mochida Pharmaceutical Co pay dividends?

Mochida Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Mochida Pharmaceutical Co?

Mochida Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Mochida Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 83.96 JPY are expected. This corresponds to a dividend yield of 2.43 %.

In which sector is Mochida Pharmaceutical Co located?

Mochida Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mochida Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mochida Pharmaceutical Co from 12/1/2024 amounting to 40 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Mochida Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Mochida Pharmaceutical Co in the year 2023?

In the year 2023, Mochida Pharmaceutical Co distributed 80 JPY as dividends.

In which currency does Mochida Pharmaceutical Co pay out the dividend?

The dividends of Mochida Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mochida Pharmaceutical Co

Our stock analysis for Mochida Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mochida Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.